On October 28, 2025, REINHART PARTNERS, LLC. disclosed a purchase of 91,788 shares of Axcelis Technologies (ACLS 1.67%), valued at approximately $7.39 million. This transaction, based on the third-quarter 2025 average price, represents 0.24% of the fund’s reportable assets under management (AUM).
The fund now holds 1,610,332 shares, valued at $157.23 million, making Axcelis its largest holding at 5.1% of AUM.
What happened
A U.S. SEC filing dated October 28, 2025, revealed that REINHART PARTNERS, LLC. increased its stake in Axcelis Technologies by 91,788 shares during Q3 2025. The trade, estimated at $7.39 million, elevated the fund’s holdings to 1,610,332 shares, with a market value of $157.23 million.
What else to know
The purchase elevated Axcelis’ share of the fund’s 13F reportable AUM to 5.1%, surpassing other holdings such as IDCC ($142.36 million) and SIMO ($142.30 million). Axcelis’ stock price stood at $83.25 as of October 27, 2025-a 7.6% annual decline, underperforming the S&P 500 by 25.8 percentage points.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close October 27, 2025) | $83.25 |
| Market capitalization | $2.58 billion |
| Revenue (TTM) | $896.09 million |
| Net income (TTM) | $158.49 million |
Company snapshot
Axcelis Technologies specializes in ion implantation equipment, a critical component in semiconductor manufacturing. Its products include high-energy, high-current, and medium-current implanters, alongside aftermarket services such as maintenance, upgrades, and training.
The company derives revenue from direct equipment sales and ongoing service contracts, targeting semiconductor manufacturers globally. Its focus on a narrow technical niche-ion implantation-has established it as a reliable supplier to major industry players.
Foolish take
Investors, particularly those with long-term perspectives, often find opportunities in less visible sectors. Axcelis’ recent rise in Reinhart Partners’ portfolio suggests a belief in its long-term prospects, despite a 8% annual decline in stock value. The company’s specialization in a single, essential process within chip production-ion implantation-grants it a unique position in an industry dominated by broader equipment firms.
Its reliance on a narrow technical expertise, while limiting diversification, also creates a barrier to entry for competitors. As demand for power semiconductors grows-driven by electric vehicles and industrial applications-Axcelis may benefit from its established client base and recurring service revenue. Yet, its performance remains tethered to the cyclical nature of the semiconductor market.
Glossary
AUM: Total value of investments managed by a fund.
13F reportable AUM: Portion of a fund’s assets subject to quarterly SEC disclosure.
Post-trade stake: Holdings in a company after a transaction.
Aftermarket lifecycle services: Maintenance, upgrades, and support for equipment post-sale.
Ion implantation equipment: Tools that alter semiconductor material properties via ion bombardment.
Filing: Official document detailing financial activity.
Mission-critical: Essential to operational success.
TTM: Trailing twelve months.
Stake: Ownership interest in a company.
Read More
- The Unexpected Triumph of Novo Nordisk: A Dividend Hunter’s Delight
- Gold Rate Forecast
- XRP On The Brink: Are We About To Witness Crypto Fireworks Or Just Another Fizzle? 🎭
- General Hospital Recap, July 23 Episode: Drew Suspects Willow of Stalking Daisy
- Superman Lore Changed Forever? YOU WON’T BELIEVE WHAT HAPPENS!
- AI Investing Through Dan Ives’ Lens: A Revolutionary ETF
- Bitcoin’s Paradox: Billionaire Buys, Price Stagnates
- Brent Oil Forecast
- Tokenized Shares: Crypto’s Mirage of Innovation
- Big Sell on Big Data: When Even the Suits Say ‘Enough’s Enough’
2025-10-31 05:13